Free Trial
→ BSEM: From OTC to Nasdaq Contender! (From Huge Alerts) (Ad)tc pixel
NASDAQ:HOTH

Hoth Therapeutics 6/3/2026 Earnings Report

Hoth Therapeutics logo
$0.68 +0.02 (+3.77%)
As of 11:55 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Hoth Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.14
Beat/Miss
N/A
One Year Ago EPS
N/A

Hoth Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Hoth Therapeutics Announcement Details

Quarter
Date
6/3/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Hoth Therapeutics Earnings Headlines

Hoth Therapeutics Launches Rocket One Space Subsidiary Initiative
May 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/hoth-therapeutics-launches-rocket-one-space-subsidiary-initiative?utm_source=marketbeat.com&utm_medium=referral
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients
May 5, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/hoth-therapeutics-secures-european-authorization-in-spain-for-ht-001-phase-2a-trial-as-interim-data-show-strong-efficacy-in-cancer-patients-302762976.html
Musk’s Next $4 Trillion Takeover Target – It’s Stranger than you Think
Tech analyst Ian King - who called an early Tesla trade that returned up to 1,000% in just over a year - says a single move by Elon Musk could reshape the monetary system within weeks. King has released a new presentation outlining what he believes is one of the most significant wealth-building opportunities in decades, and it's available free of charge right now.tc pixel
May 12 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Hoth Therapeutics (NASDAQ:HOTH) Rating Lowered to "Strong Sell" at Wall Street Zen
May 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30752844
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
April 14, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/hoth-therapeutics-hoth-reports-positive-ht-va-crada-data-gdnf-reprograms-liver-fat-metabolism-shuts-down-fat-creation-gene-and-activates-fat-burning-pathways-outperforming-semaglutide-302741263.html
REPL, HOTH, ONCO stocks hit 52-week lows: What's driving the selloff in these biotech plays?
April 14, 2026  |  msn.comhttps://www.msn.com/en-us/health/general/repl-hoth-onco-stocks-hit-52-week-lows-what-s-driving-the-selloff-in-these-biotech-plays/ar-AA20Q335
See More Hoth Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hoth Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hoth Therapeutics and other key companies, straight to your email.

About Hoth Therapeutics

Hoth Therapeutics (NASDAQ:HOTH) is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis. The company holds exclusive worldwide licenses for a range of small molecules and biological compounds sourced from leading academic institutions and research organizations. By advancing these assets through preclinical studies and early-stage clinical trials, Hoth aims to validate therapeutic potential and move products toward regulatory milestones and eventual commercialization.

Founded in 2018 and headquartered in New York, Hoth Therapeutics operates through strategic collaborations with universities, entrepreneurial biotech firms and contract research organizations. The company’s management team brings expertise in drug development, regulatory affairs and commercial strategy, positioning Hoth to navigate the complexities of clinical advancement and market entry. With a focus on specialized delivery technologies and precision formulations, Hoth seeks to address unmet medical needs and deliver innovative treatment options to patients worldwide.

View Hoth Therapeutics Profile
Earnings Tools